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Intravenous immunoglobulin (IVIg) therapy is currently the only established treatment in
patients with multifocal motor neuropathy (MMN), and many patients have an IVIg-dependent
fluctuation. We aimed to investigate the efficacy and safety of every 3 week IVIg (1.0 g/kg) for
52 weeks. This study was an open-label phase 3 clinical trial, enrolling 13 MMN patients. After
an induction IVIg therapy (0.4 g/kg/d for 5 consecutive days), maintenance dose (1.0 g/kg) was
given every 3 weeks for 52 weeks. The major outcome measures were the Medical Research
Council (MRC) sum score and hand-grip strength at week 52. This trial is registered with
ClinicalTrials.gov, number NCT01827072. At week 52, 11 of the 13 patients completed the
study, and all 11 had a sustained improvement. The mean (SD) MRC sum score was 85.6 (8.7) at
the baseline, and 90.6 (12.8) at week 52. The mean grip strength was 39.2 (30.0) kPa at the
baseline and 45.2 (32.8) kPa at week 52. Two patients dropped out because of adverse event
(dysphagia) and decision of an investigator, respectively. Three patients developed coronary
spasm, dysphagia, or inguinal herniation, reported as the serious adverse events, but considered
not related with the study drug. The other adverse effects were mild and resolved by the end of
the study period. Our results show that maintenance treatment with 1.0 g/kg IVIg every 3 week
is safe and efficacious for MMN patients up to 52 weeks. Further studies are required to inves-
tigate optimal dose and duration of maintenance IVIg for MMN.
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1 | INTRODUCTION
Multifocal motor neuropathy (MMN) is an immune-mediated periph-
eral neuropathy, characterized by progressive asymmetric distal mus-
cle weakness predominantly in the upper extremities, and pure motor
involvement.1,2 Current therapeutic options for MMN are limited, and
intravenous immunoglobulin (IVIg) therapy is only one established
treatment; as MMN patients do not respond to corticosteroids or
plasma exchange.3,4
So far, 5 randomized, placebo-controlled trials of IVIg for MMN
have shown significant short-term improvement in muscle strength,
up to 12 weeks.5–9 Based on these data, the joint European Federa-
tion of Neurological Societies/Peripheral Nerve Society (EFNS/PNS)
taskforce recommended IVIg (2 g/kg) as a first-line treatment for
MMN.1 The taskforce also proposed that “if this induction therapy is
effective, repeated IVIg should be considered with the frequency of
maintenance therapy dose are 1 g/kg every 2-4 weeks, or 2 g/kg
every 1-2 months”. However, there is limited evidence for the dose
and interval of maintenance IVIg.
No long-term clinical trials that investigated the efficacy and
safety of IVIg in MMN have been performed. Four retrospective stud-
ies have described MMN patients who have received repeated IVIg
therapy over several years, and suggested that it may be used as the
long-term treatment option for MMN.10–13 In these reports, the IVIg
regimen, interval, and treatment response varied among patients;
some experienced sustained remission and others had gradual pro-
gression of muscle weakness presumably because of Wallerian degen-
eration. The aim of this clinical trial is to study the efficacy and safety
of maintenance IVIg (1.0 g/kg every 3 weeks) for 52 weeks in patients
with MMN.
2 | MATERIALS AND METHODS
2.1 | Study design and patients
This study was a multi-center, single-arm open phase 3 trial con-
ducted at 11 Japanese tertiary hospitals. The study procedures were
in accordance with the Declaration of Helsinki, and Japanese Good
Clinical Practice criteria, and approved by the internal review board of
each hospital. This study is registered with ClinicalTrials.gov, number
NCT01827072.
A total of 13 patients with definite or probable MMN according
to the EFNS/PNS clinical diagnostic criteria were enrolled.4 The inclu-
sion criteria were defined as (1) requiring a high-dose IVIg treatment
(having declining motor function), (2) no additional immunotherapy, or
if already treated, not increasing dose of agents for MMN from
30 days prior to consent, (3) at week 4 in the induction period, Medi-
cal Research Council (MRC) sum score14 in 2 or more muscles
improved by 1 point or more, compared to that on week 1 (before
treatment) in the induction period, (4) age 20 years or older. The main
exclusion criteria were receiving (1) plasma exchange within 3 months
prior to consent, (2) natalizumab or rituximab within 6 months prior to
consent, (3) interferon beta within 6 months prior to consent, (4) high-
dose IVIg (1.0 g/kg or more) within 8 weeks prior to consent, and
(5) any IVIg treatment within 3 weeks prior to consent.
2.2 | Procedures
The study design and trial profile are shown in Figure 1. After screen-
ing, IVIg (0.4 g/kg/d for consecutive 5 days) was administered as the
induction treatment. This visit was regarded as week 1 in the induc-
tion period. After 3 weeks, IVIg was then administered (1.0 g/kg/d for
1 day, or 0.5 g/kg/d for consecutive 2 days) as the maintenance treat-
ment. This visit was regarded as week 4 in the study. Glovenin-I
(freeze-dried polyethylene glycol-treated human immunoglobulin,
Nihon Pharmaceutical Co., Ltd., Tokyo, Japan) was used for mainte-
nance treatment. The maintenance IVIg was administrated every
3 weeks from week 4 to week 49 in the maintenance period, with
observation conducted until week 52. If additional treatment for
MMN was needed, the patient dropped out.
For neurological assessment, MRC sum score, hand-grip strength,
and Guy's Neurological Disability Scale (GNDS) score15 were assessed
at each visit. Each neurological assessment, except at week 52, was
conducted before administration of IVIg.
FIGURE 1 Study design and trial profile
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2.3 | Outcome measures
The outcome measures were MRC sum score, hand-grip strength
score, and GNDS score. Difference in the mean scores at week 1 and
week 52 was calculated. These measures were not distinguished as
primary and secondary because the number of MMN patients
included in this trial was small. Safety assessments included any
adverse event during the study period.
2.4 | Data analyses
Analyses were performed by the full analysis set which included all
patients who received the drug at least once. Missing data of MRC
sum score, hand-grip strength, and GNDS score were input by data at
the last visit (the last observation carried forward method). Confi-
dence interval (CI) was calculated using the Clopper-Pearson exact
method for both periods. The target number of 10 patients was set in
view of the rarity of MMN. All analyses were performed with the sta-
tistical software package SAS, release 9.2 (SAS Institute Inc., Cary,
North Carolina). Statistical comparison was not performed because of
the small number of patients included.
3 | RESULTS
3.1 | Patient disposition
The study was conducted from June 2013, and ended in June 2015. A
total of 15 patients were screened. Two patients were ineligible, and
the remaining 13 were enrolled (Figure 1); 12 of them were
responders to prior IVIg treatment (2.0 g/kg), and the remaining 1 was
treatment-naïve. During the study, 2 patients discontinued the study
because of an adverse event (dysphagia) and decision of the investiga-
tor (slight decline of muscle strength), respectively. Of the 13 patients,
11 completed the 52-week study.
Table 1 shows patients' baseline characteristics. Eight patients
had definite MMN and 5 had probable MMN. The mean age was
60 years (range, 44-77 years) and the mean disease duration was
54 months (range, 7-205 months); 92% of the patients had received
IVIg treatment before the study. The mean baseline serum IgG level
was 1296 mg/dL (normal range, 900-1800 mg/dL).
3.2 | Efficacy
Results of the outcome measures are shown in Table 2. The mean
value of MRC sum score, hand-grip strength, and GNDS score
improved from the baseline (week 1) to week 52, except GNDS
lower limb score. The sequential changes in the MRC sum score,
hand-grip strength, and GNDS score are shown in Figure 2. All
measures improved after induction therapy and the improvement
continued through week 52 in 11 of the 13 patients. Whereas
some fluctuation of the measures occurred during maintenance
IVIg treatment, the 11 patients finally had sustained improvement
at week 52, the measure being similar to those at the baseline
(week 4). Serum IgG levels were higher at week 4 than those at
week 1, and maintained at approximately 2000 mg/dL up to
week 52.
3.3 | Safety
A total of 12 (92.3%) of the 13 patients experienced adverse events
(95% CI: 64.0%-99.8%). Table 3 shows details of adverse events with
the incidence of 15% or more. Frequent events were nasopharyngitis
(38.5%), headache (23.1%), and contusion (23.1%). Additionally,
adverse drug reactions were observed in 69.2% (9/13 patients, 95%
CI, 38.6%-90.9%). No death occurred during the study.
Three patients experienced serious adverse events, including cor-
onary artery stenosis (n = 1), dysphagia (n = 1), and inguinal hernia
(n = 1). None of them was considered to relate with IVIg.
TABLE 1 Demographics and baseline disease characteristics
Category
All patients
(n = 13)
Gender (%) Man 10 (76.9)
Age (y) <65 (%) 8 (61.5)
≥65 (%) 5 (38.5)
Mean (SD) 60.3 (10.9)
Range 44-77
Duration of
MMN (mo)
Mean (SD) 54.1 (54.8)
Range 7-205
Number of relapse
over the 3 years
prior to consent
Mean (SD) 6.9 (6.2)
Range 1-20
MMN treatment history (%) IVIg 12 (92.3)
Plasma
exchange
1 (7.7)
Others 3 (23.1)
MMN diagnostic type Definite (%) 8 (61.5)
Probable (%) 5 (38.5)
MRC sum score on week 1 Mean (SD) 85.6 (8.7)
Range 72-98
MRC sum score on week 4 Mean (SD) 90.5 (9.3)
Range 73-100
Hand-grip strength
(kPa) on week 1
Dominant Mean (SD) 39.2 (30.0)
Range 8-97
Non-dominant Mean (SD) 29.8 (22.7)
Range 0-74
Hand-grip strength
(kPa) on week 4
Dominant Mean (SD) 49.6 (31.8)
Range 10-110
Non-dominant Mean (SD) 39.5 (26.5)
Range 0-81
GNDS sum score on week 1 Mean (SD) 3.4 (1.4)
Range 2-6
GNDS sum score on week 4 Mean (SD) 2.6 (1.3)
Range 1-5
Previous medical history No 7 (53.8)
Yes 6 (46.2)
Serum IgG concentration
(mg/dL) on week 1
Mean (SD) 1296 (321.8)
Range 888-1955
GNDS, Guy's Neurological Disability Scale; IVIg, intravenous immunoglob-
ulin; MMN, multifocal motor neuropathy; MRC, Medical Research Council.
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4 | DISCUSSION
The present study showed that after conventional induction IVIg ther-
apy, maintenance IVIg treatment (1.0 g/kg) every 3 week resulted in
sustained clinical improvement for 52 weeks. The results were sup-
ported by sequential findings of MRC sum score, grip strength, and
GNDS score. The maintenance IVIg therapy was not associated with
clinically significant adverse effects. Our results show the long-term
efficacy and safety of the maintenance IVIg.
In previous retrospective studies, a variable maintenance IVIg reg-
imens, such as 1.0 g/kg every 2 to 4 weeks, or 2 g/kg every 1 to
2 months, were used dependent on patients' condition. Whereas dis-
ease activity, immunoglobulin metabolism, and response to treatment
are presumably different among patients with MMN, the optimal dose
and interval may be determined according to patients' situation. Nev-
ertheless, this study revealed uniform regular maintenance IVIg
administration was successful in almost of the MMN patients enrolled.
The regimen used in this trial can be an option to achieve sustained
remission in MMN at least for 52 weeks.
In patients with chronic inflammatory demyelinating polyneuropa-
thy (CIDP), approximately 25% of patients have long-lasting remission
without immunological treatment,16,17 and prolonged maintenance
therapy could be over treatment. However, such remitting course is
rare for MMN,10 and MMN patients may require maintenance therapy
for more than 52 weeks. Therefore the duration of IVIg therapy, as
well as, the optimal regimen, for longer maintenance IVIg for MMN
patients should be evaluated in future studies.
A recent clinical trial for CIDP using the same maintenance dose
(1.0 g/kg) and interval (every 3 weeks) for 52 weeks has also shown
similar long-term efficacy.18 In that study, 2 of the 49 enrolled elderly
patients with hypertension or diabetes developed cerebral infarction.
Whereas thromboembolic events did not occur in the present study,
hyperviscosity-induced thrombotic complications should be carefully
monitored during a long-term IVIg treatment.
In conclusion, 52-week maintenance IVIg therapy appears to be
safe and efficacious to prevent a relapse for MMN patients. The
FIGURE 2 Transition diagram of symptoms in multifocal motor
neuropathy (MMN). (A) Medical Research Council (MRC) sum score,
(B) hand-grip strength of dominant hand, (C) Guy's Neurological
Disability Scale (GNDS) sum score. The visit interval was every
3 weeks in maintenance period. Error bars represent SEM
TABLE 2 Efficacy of IVIg in patients with MMN
Induction
period (n = 13)
Maintenance
period (n = 13)
Week 1 Week 4 Week 52
MRC sum score 85.6 (8.7) 90.5 (9.3) 90.6 (12.8)
Hand-grip strength (kPa)
Dominant hand 39.2 (30.0) 49.6 (31.8) 45.2 (32.8)
Non-dominant hand 29.8 (22.7) 39.5 (26.5) 41.1 (28.6)
GNDS score
Upper limb 2.8 (0.8) 2.2 (1.2) 1.8 (1.4)
Lower limb 0.6 (1.0) 0.5 (0.7) 0.8 (1.1)
Sum score 3.4 (1.4) 2.6 (1.3) 2.7 (2.3)
Serum IgG (mg/dL) 1296 (322) 2070 (341) 1974 (363)a
Data are shown as mean (SD). GNDS, Guy's Neurological Disability Scale;
IVIg, intravenous immunoglobulin; MMN, multifocal motor neuropathy;
MRC, Medical Research Council.
a n = 11.
TABLE 3 Adverse events reported in ≥15% of patients
Total patients N = 13
Patients developing adverse events N = 12
Rate of developing adverse events 92.3%
Total number of developing
adverse events
N = 79
Adverse event name (PT) Number of patients (%)
Nasopharyngitis 5 38.5
Headache 3 23.1
Contusion 3 23.1
Epistaxis 2 15.4
Dental caries 2 15.4
Diarrhea 2 15.4
Dysphagia 2 15.4
Rash 2 15.4
Medical dictionary for Regulatory Activities (MedDRA), version 18.0.
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longer-term safety and efficacy, and need of dose adjustment should
be investigated in future studies.
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